Business Context and Reporting Period
This Form 8-K Current Report was filed by OraSure Technologies, Inc. on December 18, 2003. The report discloses material events occurring between December 15, 2003, and December 17, 2003, regarding regulatory progress and manufacturing operations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational and regulatory events rather than financial performance data.
Material Changes and Operational Events
- HIV-2 Claim Submission: On December 15, 2003, the Company submitted additional data to the U.S. Food and Drug Administration (FDA) to support an HIV-2 claim for its OraQuick Rapid HIV-1 Antibody Test.
- Manufacturing Facility Inspection: On December 17, 2003, the FDA successfully completed a facility inspection required for the transfer of the Company's in-house and third-party contract manufacturing operations from Oregon to Bethlehem, Pennsylvania.
Outlook, Risks, and Management Commentary
Management commentary is limited to the successful completion of the FDA facility inspection and the submission of data for the HIV-2 claim. These events indicate progress in regulatory compliance and the consolidation of manufacturing capabilities. No specific financial guidance, risks, or contingencies were detailed in this filing.
Investor Verification Checklist
- Verify the status of the FDA review for the OraQuick HIV-2 claim following the data submission.
- Confirm the timeline for the full operational transfer of manufacturing from Oregon to Pennsylvania.
- Review the attached press releases (Exhibits 99.1 and 99.2) for detailed technical or operational specifics not included in the summary.